Read More Pharma Industry News GSK agrees up to $750m Chimagen deal to deepen multiple myeloma pipeline GSK is paying up to $750 million for a trispecific multiple myeloma asset, with early clinical data set to determine whether the deal creates value. byPallavi MadhirajuSeptember 16, 2026